期刊文献+

关节康口服液对大鼠佐剂性关节炎的治疗作用及胃黏膜保护作用研究 被引量:1

Research on Clinical Treatment Effect of Arthrosis Healing Oral Liquor on Osteoarthritis and Stomachic Mucosa Protection
下载PDF
导出
摘要 目的评价关节康口服液对疼痛性关节炎的疗效和安全性。方法采用弗氏完全佐剂制备大鼠佐剂性关节炎(AA)模型,观察关节康对AA大鼠的治疗作用和胃肠保护作用。结果关节康口服液不仅能抑制AA大鼠的原发性炎症,而且对继发性炎症也有抑制作用,对胃黏膜的损伤程度也远小于英太青(P<0.01)。结论关节康口服液对AA有较好的治疗作用,且对胃黏膜具有一定的保护作用。 Objective To study the effect and safety of Arthrosis Healing Oral Liquor(AHOL) in curing aching arthritis. Methods Complete Freund's adjuvant(CFA) was adopted in rat adjuvant arthritis, AA model, to observe the therapeutic effect and protective effect of AHOL on gut in AA rat, and to compare with the group taking Yingtaiqing. Results No obvious difference existed in the effect of anti-inflammation and pain-reliveing between the AHOL group and the control group. AHOL played the inhibitory function on essential inflammation and secondary inflammation on AA rat, and has obviously inhibitory function to rat synovial membrane PGE2, but with no obvious influence on stomachic mucosa PGE2. Conclusion AHOL has good therapeutic effect on rat adjuvant arthritis and certain protective effect on stomachic mucosa.
出处 《中国药业》 CAS 2007年第22期26-27,共2页 China Pharmaceuticals
基金 2003年苏州市社会发展项目 项目编号:SZDD315
关键词 关节康口服液 佐剂性关节炎 前列腺素E2 Arthrosis Healing Oral Liquor(AHOL) adjuvant arthritis PGE2
  • 相关文献

参考文献3

二级参考文献49

  • 1刘传珍,水正.中医药治疗老年类风湿性关节炎所致骨质...[J].中国骨伤,1993,6(1):17-20. 被引量:18
  • 2聂志伟,路遥.蚂蚁制剂治疗类风湿性关节炎的疗效对比观察[J].辽宁中医杂志,1995,22(7):304-305. 被引量:18
  • 3[1]Lichtenstein D, Syngal S, Wlfe MM. Non-steroidal antiinflammatory drugs and the gastrointestinal tract. Arthritis Rherm,1995;38:1:5~18.
  • 4[2]Bjarnason I, Macpherson A, Somasundaram S, et al. Lower bowel toxicity of non-steroidal anti-inflammatory drugs. Lewis A: Non-steroidal Anti-Inflammatory Drugs, Mechanisms and Clinical Uses. New York: NY, Marcel Dekker, 1994;145~157.
  • 5[3]Marie R, Griffin, MD. Epidemiology of non-steroidal antiinflammatory drug-associated gastrointestinal injury. Am J Med.1998;104: 23~28.
  • 6[4]Fujiwara Y, Schmassman A, Arakawa T, et al. Indomethacin interferes with epidermal growth factor binding and proliferative response of KATO Ⅲ cells. Digestion, 1995;56:364~369.
  • 7[5]Henry D, Robertson J. Non-steroidal anti-inflammatory drugs and peptic ulcer hospitalization rates in New South Wales.Gastroenterology. 1993; 104:1083~ 1091.
  • 8[6]Fries JF, Williams CA, Michel BA et al. Nonsteroidal antiinflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med, 1991 ;91:213 ~222.
  • 9[7]Gutthamm SP, García LA, Raiford DS. Individual nonsteroidal anti-inflammatory drugs and the risk of hospitalization for upper gastrointestinal bleeding and perforation in saskatche wan: a nested case-control study. Pharmacoepidemiol Drug Safety. 1994;3:S63.
  • 10[8]Loeb DS, Talley NJ, Ahlquist DA, et al. Long-term non-steroidal anti-inflammatorydrug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology, 1992;102 :1899~1905.

共引文献122

同被引文献14

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部